Drug intelligence / Profile preview

ganitumab + rilotumumab

Development stage: Unknown
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A combination of two fully human monoclonal antibodies for oncology research: ganitumab is an anti–insulin-like growth factor 1 receptor (IGF1R) antibody that blocks IGF-1/IGF-2 signaling, and rilotumumab is an anti–hepatocyte growth factor (HGF) antibody that inhibits HGF binding to the MET receptor. Evaluated primarily in combination regimens (e.g., with panitumumab or platinum–etoposide) for metastatic colorectal cancer and extensive-stage small-cell lung cancer; clinical studies did not demonstrate clear improvement in overall outcomes versus comparators, though safety was generally tolerable in tested regimens.[2][1][3]

Other names: ganitumab and rilotumumab

Targets

IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on ganitumab + rilotumumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ganitumab + rilotumumab.

Explore the full profile